Phosphorylcholine-Tuftsin Conjugate for Steroid-Sparing Ocular Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular inflammation, such as steroids, have severe side effects and there is a need for alternative methods that do not rely on them, particularly for direct administration to the eye with very low doses of medication.
Innovation Solution
Administering a pharmaceutical composition comprising a phosphorylcholine-tuftsin conjugate, which includes a phosphorylcholine moiety or derivative and tuftsin or derivative, to the eye to treat or prevent ocular inflammation, potentially reducing the dose of steroids required.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids are used to treat ocular inflammation, then inflammation is reduced, but severe side effects occur
Solution Approach 1:
The patent changes the chemical parameter from steroids to phosphorylcholine-tuftsin conjugate, a completely different molecular structure with immunomodulatory properties. This parameter change maintains anti-inflammatory efficacy while eliminating steroid-related side effects through a different mechanism of action
Solution Approach 2:
The invention uses a composite molecule combining phosphorylcholine and tuftsin through chemical conjugation. This composite structure integrates the immunomodulatory properties of phosphorylcholine with the cell-penetrating and anti-inflammatory properties of tuftsin, achieving synergistic anti-inflammatory effects without steroid side effects
2Reliability
If conventional treatments are used for ocular inflammation, then inflammation is treated, but high doses of medication are required
Solution Approach 1:
The patent changes the dosing parameter from milligram-range steroid doses to microgram-range TPC doses. This parameter change is enabled by the superior potency and bioavailability of the phosphorylcholine-tuftsin conjugate, which achieves therapeutic effects at much lower concentrations
Solution Approach 2:
The phosphorylcholine-tuftsin conjugate exhibits self-amplifying immunomodulatory effects where initial low-dose administration triggers regulatory T cell responses that sustain anti-inflammatory effects, reducing the need for continuous high-dose medication
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate effectively reduces ocular inflammation by modulating cytokine secretion, achieving inflammation reduction comparable to or greater than steroids while minimizing side effects, and allows for lower steroid doses.
Implementation Method 1
Tuftsin-PhosphorylCholine (TPC) is a novel bi-specific small molecule with immunomodulatory activities
Data Source
AI summary
Methods of treating or preventing ocular inflammation in a subject in need thereof, and methods of reducing the dose of a steroid administered to a subject suffering from ocular inflammation, comprising administering to an eye of the subject a pharmaceutical composition a phosphorylcholine-tuftsin conjugate comprising at least one phosphorylcholine moiety or a derivative thereof and tuftsin or a derivative thereof are provided.